TELIX Pharmaceuticals Ltd (TLX.AU) — Quality & forensics
As of 2026-11-19 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 17
- Quality 30
- Growth 48
- Balance sheet 34
- Cash quality 39
- Capital allocation 34
- Momentum 51
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the TLX.AU chart & overview
FAQ · from the current data · as of 2026-11-19
Quick answers
What is TELIX Pharmaceuticals Ltd's Closelooknet quality reading?
The composite reads 36/100 across 7 modules, as of 2026-11-19: valuation 17, quality 30, growth 48, balance sheet 34, cash quality 39, capital allocation 34, momentum 51. Closelooknet scores are research diary readings, not ratings or investment advice.
What is TELIX Pharmaceuticals Ltd's Altman Z-Score?
4.25, which sits in the safe zone (above 2.99) as of 2026-11-19. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is TELIX Pharmaceuticals Ltd's Piotroski F-Score?
3 of 9, as of 2026-11-19. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does TELIX Pharmaceuticals Ltd's Beneish M-Score indicate?
-2.09 — below the −1.78 manipulation-risk threshold, as of 2026-11-19. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ONC BeOne Medicines AGindustry
- REGN Regeneron Pharmaceuticals Incindustry
- ARGX.BR Argen-Xindustry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- VRDN Viridian Therapeutics Incindustry
- SLS Sellas Life Sciences Group Incindustry
- VCEL Vericel Corp Ordindustry
- INSM Insmed Incindustry
- REPL Replimune Group Incindustry
- ADMA ADMA Biologics Incindustry
- XNCR Xencor Incindustry
- KOD Kodiak Sciences Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- RPRX Royalty Pharma Plcindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- ORKA Oruka Therapeutics, Inc.industry
- IRON Disc Medicine Inc.industry
- NEU.AU Neuren Pharmaceuticals Ltdindustry